Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trodusquemine

Drug Profile

Trodusquemine

Alternative Names: MSI-1436; Produlestan; Trodulamine

Latest Information Update: 18 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genaera Corporation
  • Developer DepYmed; Genaera Corporation; North Shore-Long Island Jewish Health System
  • Class Anorectics; Antihyperglycaemics; Antivirals; Biogenic amines; Cholestanes; Obesity therapies; Polyamines
  • Mechanism of Action Adrenergic uptake inhibitors; Apoptosis stimulants; Dopamine uptake inhibitors; Neuropeptide Y modulators; Protein-tyrosine-phosphatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Breast cancer
  • Discontinued Diabetes mellitus; HIV infections; Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 12 Jul 2019 Ohr Pharmaceutical has merged with NeuBase Therapeutics to form NeuBase Therapeutics
  • 28 May 2019 No recent reports of development identified for phase-I development in Breast-cancer(Metastatic disease, Second-line therapy or greater) in USA (IV)
  • 14 May 2018 DepYmed terminates a phase I trial in Breast cancer (Metastatic disease, Second-line therapy or greater) in USA due to lack of interest by sponsor (IV) (NCT02524951)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top